GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sun Pharmaceutical Industries Ltd

Sun Pharma Q2 FY27 Standalone Profit at ₹8,712.9 Million

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 30 Oct 2026, 02:14 PM IST  ·  BSE ID: 7bbcaf67-e404-4ffb-b7fd-07ff385fdb0a
View Original BSE Filing (PDF)
💡
In Simple Terms
Sun Pharma reported increased standalone profits and revenues for the second quarter and first half of the current financial year.
🤖 AI Summary
  • Standalone net profit for Q2 FY27 was ₹8,712.9 Million, compared to ₹5,642.2 Million in Q2 FY26.
  • Total revenue from operations reached ₹61,419.2 Million for the quarter ended September 30, 2026.
  • Half-year standalone net profit stood at ₹19,864.3 Million, compared to ₹13,092.8 Million in H1 FY26.
  • Half-year total revenue from operations was ₹118,830.5 Million, up from ₹101,429.9 Million in H1 FY26.
  • The Board approved the unaudited standalone and consolidated financial results for the period.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Profit for the Period (Q2 FY27)
₹8,712.9 Million
54.42%
Total Revenue from Operations (Q2 FY27)
₹61,419.2 Million
35.04%
Standalone Profit for the Period (H1 FY27)
₹19,864.3 Million
51.72%
Total Revenue from Operations (H1 FY27)
₹118,830.5 Million
17.16%
Basic Earnings per Equity Share (Q2 FY27)
₹3.6
50.00%
Other Equity (as at 30.09.2026)
₹231,248.4 Million
Non-current Borrowings (as at 30.09.2026)
₹151,463.9 Million
🏢 How This Affects the Company
📈
Business Impact
The increase in revenue from operations suggests stronger sales performance, contributing to market share and operational scale. Research and development expenses were ₹4,334.8 Million for the quarter and ₹8,970.7 Million for the half-year.
💰
Financial Impact
Standalone profit for the period increased to ₹8,712.9 Million for Q2 FY27 and ₹19,864.3 Million for H1 FY27, improving overall profitability. Non-current borrowings increased from ₹134,199.9 Million as of March 31, 2026, to ₹151,463.9 Million as of September 30, 2026.
⚙️
Operational Impact
Total expenses for the quarter were ₹50,199.4 Million, showing efficient cost management relative to revenue growth. Employee benefits expense for the quarter was ₹8,520.0 Million.
⚠️
Risk Impact
The net gain on foreign currency transactions decreased to (₹878.1) Million for the quarter from (₹4,816.2) Million in the prior year comparable quarter, indicating changes in currency exposures or movements.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on these financial results.
👤
Who Is Affected
All existing shareholders are affected by the improved financial performance, as reflected by the increase in basic and diluted earnings per share to ₹3.6 for Q2 FY27 from ₹2.4 in Q2 FY26.
🔍
Management Signal
The Board's approval of the unaudited financial results and the subsequent release of a press release and earnings presentation signal transparency and adherence to regulatory disclosure requirements.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — assess sustained profit and revenue growth.
Consolidated financial results — review full business performance across entities.
Management commentary in earnings presentation — look for operational outlook.
LOW RISK The financial results show robust growth with no explicit new risks disclosed.
💡 Investor Takeaway
Sun Pharmaceutical Industries reported standalone net profit of ₹8,712.9 Million for Q2 FY27, up 54.42% from ₹5,642.2 Million in Q2 FY26. Total revenue from operations increased to ₹61,419.2 Million, a 35.04% YoY growth, indicating strong quarterly performance.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Profit for the Period increased to ₹8,712.9 Million for Q2 FY27 from ₹5,642.2 Million in Q2 FY26, a 54.42% YoY growth.
  • Total Revenue from operations grew to ₹61,419.2 Million for Q2 FY27 from ₹45,481.1 Million in Q2 FY26, a 35.04% YoY increase.

⚠️ Concerns

  • Exceptional items of ₹315.3 Million were reported for the half year ended September 30, 2026, not present in the comparable prior quarter.
  • Net gain on foreign currency transactions for the quarter was (₹878.1) Million, a decrease compared to (₹4,816.2) Million in Q2 FY26.
📅 Company Track Record
Sun Pharma's Q1 FY27 standalone profit increased to ₹11,151.4 Million, up 49.67% YoY. The current Q2 FY27 filing continues this trend, with standalone profit for the period increasing by 54.42% YoY.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Sun Pharmaceutical Industries Ltd's standalone profit for Q2 FY27?
Sun Pharmaceutical Industries Ltd reported a standalone profit for the period of ₹8,712.9 Million for the quarter ended September 30, 2026.
What was Sun Pharmaceutical Industries Ltd's total revenue from operations for Q2 FY27?
The total revenue from operations for Sun Pharmaceutical Industries Ltd was ₹61,419.2 Million for the quarter ended September 30, 2026.
How did Sun Pharmaceutical Industries Ltd's half-year standalone profit (H1 FY27) compare to the previous year?
For the half year ended September 30, 2026, standalone profit was ₹19,864.3 Million, an increase from ₹13,092.8 Million in H1 FY26.
What were the basic earnings per equity share for Sun Pharmaceutical Industries Ltd in Q2 FY27?
The basic earnings per equity share for Sun Pharmaceutical Industries Ltd in Q2 FY27 was ₹3.6.
What was the company's total equity as of September 30, 2026?
The total equity of Sun Pharmaceutical Industries Ltd as of September 30, 2026, was ₹233,647.7 Million.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.